PEPIN RONALD 4
4 · Celldex Therapeutics, Inc. · Filed Dec 17, 2025
Insider Transaction Report
Form 4
PEPIN RONALD
Sr. VP & CBO
Transactions
- Exercise/Conversion
Common Stock
2025-12-15$9.02/sh+8,333$75,134→ 9,097 total - Exercise/Conversion
Common Stock
2025-12-15$2.78/sh+11,000$30,580→ 20,097 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2025-12-15−8,333→ 5,000 totalExercise: $9.02Exp: 2028-06-13→ Common Stock (8,333 underlying) - Exercise/Conversion
Incentive Stock Option (right to buy)
2025-12-15−11,000→ 0 totalExercise: $2.78Exp: 2029-06-19→ Common Stock (11,000 underlying)
Footnotes (4)
- [F1]On February 8, 2019, Celldex Therapeutics, Inc. effected a 1-for-15 reverse stock split of its common stock (the "Reverse Stock Split"). This option was previously reported as covering 200,000 shares at an exercise price of $0.6011 per share, but has been adjusted to reflect the Reverse Stock Split.
- [F2]Includes 764 shares of common stock acquired under the Celldex Therapeutics, Inc. 2004 Employee Stock Purchase Plan.
- [F3]As of June 13, 2022, the option is fully vested.
- [F4]As of June 19, 2023, the option is fully vested.